Answers are grounded in this paper and cite their sources.
In recent years, significant progress has been made in glucose monitoring technologies, which allow patients with type 2 diabetes mellitus (T2DM) to more accurately monitor glucose levels and respond quickly to changes. The use of new technologies in the treatment of T2DM, including flash monitoring of glycemia (FMG), helps to select the appropriate hypoglycemic therapy for a particular patient, as well as motivate them to lifestyle changes. In the presented clinical case, a patient with T2DM received basic bolus insulin therapy, however, against its background, compensation for carbohydrate metabolism was not achieved. To assess the causes of hyperglycemia, select and optimize hypoglycemic therapy, as well as motivate the patient to treat diabetes, an FMG system was installed for the patient. Against the background of monitoring, the patient began to calculate the dose of ultrashort-acting insulin, taking into account the bread units consumed, changed his diet, which allowed him to reach the target glucose values as soon as possible, after which the ultrashort-acting insulin was discontinued and metformin was added to therapy. Thus, the patient's commitment to therapy and lifestyle changes during FMG helped to achieve compensation for T2DM. This clinical case demonstrates the importance of using modern glucose monitoring technologies, as well as a combination of various treatment methods to achieve target blood glucose levels in patients with T2DM.
No takes yet. Share an insight, caveat, or question.
Титова et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: